The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows".

• Tác giả: Paolo Bironzo, Massimiliano Cani, Enrica Capelletto, Veronica Crespi, Marco Donatello Delcuratolo, Edoardo Garbo, Mario Levis, Alessandra Merlini, Andrea Mogavero, Valerio Maria Napoli, Silvia Novello, Francesco Passiglia, Maria Lucia Reale, Umberto Ricardi, Giorgio Saba, Antonio Ungaro
• Ngôn ngữ: eng
• Thông tin xuất bản: Netherlands : Cancer treatment reviews , 2025
• Bộ sưu tập: NCBI
• ID: 707998

Tóm tắt

 Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting
  the activity of less intensive regimens for frail populations
  the role of targeted therapies in oncogene-addicted tumors
  the selection of subsequent strategies at immunotherapy failure
  the efficacy of novel and intensified treatments
  the role of molecular biomarkers for patients' selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.